•Combined therapy with MUC1 mRNA nanovaccine and anti-CTLA-4 mAb could reduce immunosuppressive TME, increase the infiltration of CD8+ T cells into tumor sites, and enhance anti-tumor cytotoxic T-lymphocyte activity when compared with each monotherapy. This evidence concerns the gene MUC1 and neoplasm.